SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is the dominant topic, centered on Irth Capitals reported bid and a major U.S. franchisee joining the effort; traders are debating whether a deal will materialize, with no confirmed agreement in the discussion. The takeover hopes contrast with criticism of management and concern over weak sales, a dividend suspension, and the stocks steep decline.

TOSHI

A burst of trading volume and a recent rebound have fueled talk of a technical breakout and a possible short squeeze in TOSHI, with many holders buying dips and anticipating a move through resistance. Others point to repeated failed breakouts, weak price action, and broader crypto-market softness; talk of an upcoming announcement or listing remains speculative.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, news-unconfirmed XCN spike is driving attention, with traders reacting to a large candle and debating whether it marks a rebound or another brief pump-and-dump. Some are buying the dip and pointing to Bitcoins bounce, while skeptics say XCNs past spikes have quickly faded.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung cancer results for IMDELLTRA plus AstraZenecas IMFINZI, which reduced the risk of death in first-line extensive-stage small cell lung cancer, are driving attention. Traders see the findings as a potential growth catalyst and debate how much they could expand the drugs commercial role alongside established products such as Repatha.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and fears of disrupted oil supplies is driving attention to UCO. Traders are divided between following the bullish momentum and positioning for a pullback, with some noting that geopolitical headlines could quickly shift the oil trade.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention after reaching a new high as energy stocks outperform, with traders pointing to rising crude prices and supply risks tied to Middle East tensions and shipping disruptions. The conversation is broadly bullish on the breakout, though some traders warn the rally may be extended and question whether it can hold.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks attention centers on Phase 3 results for its partnership with Moderna: the personalized cancer vaccine added to Keytruda reduced melanoma recurrence or death risk, drawing interest in the oncology platform and potential commercial upside. Traders debate whether the results justify further gains, given high expectations, unapproved status, and questions about manufacturing complexity and expansion beyond melanoma.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 breast-cancer subgroup data presented at ESMO is drawing attention, with traders highlighting stronger progression-free survival and response results for gedatolisib combinations. Reactions are mixed: some see the findings as compelling, while others note the data builds on previously released topline results and say CELC still needs to demonstrate commercial uptake and revenue.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Holders are split between accumulating and anticipating a rebound, while skeptics point to weak momentum, limited utility, and the risk of further declines.

Anthropic

Anthropics anticipated blockbuster IPO is driving attention, with traders weighing rapid revenue growth against heavy compute commitments and reported losses. Some see a major AI-growth opportunity, while skeptics question whether the spending and intensifying competition can support the expected valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a...

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the...

Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development OfficerPR NewswireWALTHAM, Mass., Sept. 14...

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Sept. 1, 2026 WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company...

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Q32 Bio Stock Falling Wednesday?

Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.read more...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today? 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Citi raised Apple’s price target to $365 and expects stronger margins and continued market growth ahead of earnings.&nbsp;</li><li>Q32 Bio stock jumped 90% after positive Phase 2a trial results for bempikibart in severe alopecia areata.&nbsp;</li><li>CSX stock hit a record high of $49.90 after Raymond James raised its price target to $56 from $49.</li></ul>Apple Inc. (AAPL), Q32 Bio (QTTB) and CSX Corp. (CSX) each climbed to fresh 52-week highs on Monday as investors looked beyond broader market concerns and focused on earnings potential, clinical progress and improving industry conditions.&nbsp;Q32 Bio stock jumped 90%, while Apple and CSX stocks ended the session 0.6% and 0.4% higher, respectively.&nbsp;<h2 class="st-heading-2">Apple Hits Record High As Citi Raises Price Target Ahead Of Earnings&nbsp;</h2><a href="https://stocktwits.com/symbol/AAPL">Apple’s stock</a> reached a new all-time high of $323.45, extending its two straight weeks of gains after receiving renewed optimism from Wall Street analysts.Citi increased its target price on Apple shares to $365 from $315 while reiterating its ‘Buy’ rating. The firm believes Apple is in a strong position ahead of its fiscal Q3 earnings and can continue growing its market share even as overall device sales slow.&nbsp;According to Citi, the higher price target reflects improved margin expectations following Apple's recent product price increases.&nbsp;Despite the smartphone industry slowdown, Apple saw its smartphone&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-s-i-phone-and-google-pixel-q2-sales-shine-even-as-global-smartphone-market-drops-to-13-year-low/cZmCbU0R7Yp">shipments</a> rise 3% year-on-year in Q2, according to&nbsp;Counterpoint Research. Apple captured a record 20% share of the global market in the quarter, helped by strong demand for its iPhone 17 lineup.&nbsp;On Stocktwits, retail sentiment around the stock turned to ‘neutral’ from ‘bearish’ the previous day.&nbsp;<h2 class="st-heading-2">Q32 Bio Surges After Promising Hair Loss Drug Trial Results&nbsp;</h2><a href="https://stocktwits.com/symbol/QTTB">Q32 Bio stock</a> delivered the session's biggest move, hitting a 19-month high of $22.50 after reporting encouraging Phase 2a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qttb-stock-clocks-best-day-in-a-year-following-positive-alopecia-data-analyst-sees-further-200-upside/cZmCTpsR7Yq">data</a> for bempikibart in patients with severe alopecia areata (hair fall). The experimental anti-IL-7Rα therapy produced meaningful improvements in hair regrowth, including a 40% SALT-20 (a standard tool for measuring alopecia severity) response after 36 weeks.&nbsp;The company also outlined plans to pursue a registration-directed development program by the first half of 2027 and announced a $200 million public stock offering to help finance future clinical development.After the data, Wells Fargo analyst Derek Archila upgraded Q32 Bio to ‘Overweight’ from ‘Equal Weight’ and raised the price target sharply from $10 to $66. The firm said the trial results increased its confidence that bempikibart could succeed as a treatment.The firm also believes Q32 Bio could grow significantly, potentially reaching a market value of about $2 billion after the company strengthens its financial position. Retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">CSX Hits Record High As Raymond James Raises Price Target&nbsp;</h2><a href="https://stocktwits.com/symbol/CSX">CSX stock</a> reached a record high of $49.90 after Raymond James raised its price target on CSX to $56 from $49 and maintained an ‘Outperform’ rating.The firm expects the transportation company to report stronger fiscal second-quarter (Q2) results, citing operational improvements and a better setup in the freight market.According to Raymond James, the transportation sector is benefiting from tighter supply conditions even though overall demand remains relatively soft. The firm believes this imbalance could create a more favorable environment for rail operators as industry conditions continue to stabilize.However, retail sentiment toward the stock turned from ‘bearish’ to ‘neutral’ in a day.So far this year, AAPL and CSX stocks have gained 16% and 36%, respectively, while QTTB stock has surged 543%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dis-stock-gains-nearly-2-why-wells-fargo-says-disney-could-jump-40-if-it-exits-streaming/cZmzwRyR7Y0">DIS Stock Gains Nearly 2% — Why Wells Fargo Says Disney Could Jump 40% If It Exits Streaming</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Apple logo appears on the screen of a smartphone placed on a surface reflecting the new Siri logo.

Apple Inc. (AAPL), Q32 Bio (QTTB) and CSX Corp. (CSX) each climbed to fresh 52-week highs on Monday as investors looked beyond broader market concerns and focused on earnings potential, clinical progress and improving industry conditions.&nbsp;

Investors backed strong catalysts, including analyst upgrades, biotech trial results and improving freight outlooks. 


Apple Inc

CSX Corp.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$8.65
Prev Close	$8.80
Open	$8.80
Dividend Yield	0.00%
50-Day Moving Average	$11.13
Beta	0.28
Avg. Volume	934,786.48
PE Ratio	2.88

52-Week High	$23.57
52-Week Low	$1.91
Market Capitalization	$257.51M
EPS (Annual)	$2.42
Price to Book	1.94
Revenue Per Employee	$2.24M

Feed

News

Sentiment

Earnings

Fundamentals

Info

QTTB Fundamentals